Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Capital Expenditures (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Capital Expenditures for 6 consecutive years, with -$937000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 395.58% to -$937000.0 in Q4 2025 year-over-year; TTM through Sep 2025 was $1.3 million, a 125.13% increase, with the full-year FY2024 number at $359000.0, down 80.59% from a year prior.
  • Capital Expenditures was -$937000.0 for Q4 2025 at Janux Therapeutics, down from $890000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $3.9 million in Q3 2022 to a low of -$937000.0 in Q4 2025.
  • A 5-year average of $434600.0 and a median of $241000.0 in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: tumbled 654.42% in 2021, then surged 2019.05% in 2025.
  • Janux Therapeutics' Capital Expenditures stood at -$815000.0 in 2021, then skyrocketed by 352.27% to $2.1 million in 2022, then tumbled by 74.95% to $515000.0 in 2023, then tumbled by 38.45% to $317000.0 in 2024, then plummeted by 395.58% to -$937000.0 in 2025.
  • Per Business Quant, the three most recent readings for JANX's Capital Expenditures are -$937000.0 (Q4 2025), $890000.0 (Q3 2025), and -$324000.0 (Q2 2025).